Sign up here and take full advantage of MicrobiomePost‘s features.

Home » Akkermansia municiphila on the market before the end of 2022

Akkermansia municiphila on the market before the end of 2022

Patrice Cani (Université catholique de Louvain) discusses the future of Akkermansia municiphila.

Industry

Staff editor

Most recent

Scientific research

Discovering Wellmicro: pioneering breakthroughs in microbiome analysis for human health

7 June 2023

Biocodex targedys

Industry

Biocodex becomes the sole shareholder of TargEDys

6 June 2023

Scientific research

Healthy humans do not have a common blood microbiota

5 June 2023

Gastroenterology

Centenarians have a youthful gut microbiota that may help support longevity

2 June 2023

HCPs Area

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Cover instant book - Vaginome

Vaginome: understanding the vaginal microbiome. Questions & answers

Industry

Biocodex targedys

Biocodex becomes the sole shareholder of TargEDys

Pre-hypertension: from Biofarma Group a nutraceutical solution to counteract it

Read more about Industry

Biocodex targedys

Industry

Biocodex becomes the sole shareholder of TargEDys

6 June 2023

Industry

Pre-hypertension: from Biofarma Group a nutraceutical solution to counteract it

23 May 2023

Industry

MASTERing food chain microbiomes – the webinar

23 May 2023

Industry

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

16 May 2023

Industry

Ode to the people – Declaration of intent by SynBalance

4 May 2023

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

Industry

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

28 April 2023

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

Industry

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

27 April 2023

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Industry

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

26 April 2023